Literature DB >> 19148589

Micafungin-induced immune hemolysis attacks.

Tomoko Nanri1, Eisaku Iwanaga1, Satomi Fujie1, Yasuhiro Yamada1, Kentaro Horikawa1, Hiroaki Mitsuya1, Norio Asou2.   

Abstract

The echinocandins provide an attractive new option for prophylactic and empirical treatment of invasive fungal infections in patients with neutropenia after intensive cytotoxic chemotherapy or hematopoietic stem cell transplantation. We present two patients with hematological diseases who experienced massive intravascular hemolysis followed by renal failure after administration of micafungin. In indirect antiglobulin test, significant agglutination was observed when red blood cells were exposed to the mixture of micafungin and either of the patients' plasma samples, indicating that production of antibodies directed against both micafungin and red blood cell membrane induced hemolysis attack. Micafungin-mediated immune hemolysis represents an uncommon but life-threatening adverse reaction leading to renal failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19148589     DOI: 10.1007/s12185-008-0246-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  8 in total

Review 1.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

Review 2.  The changing spectrum of drug-induced immune hemolytic anemia.

Authors:  Patricia A Arndt; George Garratty
Journal:  Semin Hematol       Date:  2005-07       Impact factor: 3.851

3.  Thiopental-related immune hemolytic anemia and renal failure. Specific involvement of red-cell antigen I.

Authors:  B Habibi; R Basty; S Chodez; A Prunat
Journal:  N Engl J Med       Date:  1985-02-07       Impact factor: 91.245

4.  Immunohemolytic anemia due to antipenicillin antibodies. Report of a case.

Authors:  M A Swanson; D Chanmougan; R S Schwartz
Journal:  N Engl J Med       Date:  1966-01-27       Impact factor: 91.245

5.  On the mechanisms of sensitization and attachment of antibodies to RBC in drug-induced immune hemolytic anemia.

Authors:  A Salama; C Mueller-Eckhardt
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

6.  Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.

Authors:  Ernst-Rüdiger Kuse; Ploenchan Chetchotisakd; Clovis Arns da Cunha; Markus Ruhnke; Carlos Barrios; Digumarti Raghunadharao; Jagdev Singh Sekhon; Antonio Freire; Venkatasubramanian Ramasubramanian; Ignace Demeyer; Marcio Nucci; Amorn Leelarasamee; Frédérique Jacobs; Johan Decruyenaere; Didier Pittet; Andrew J Ullmann; Luis Ostrosky-Zeichner; Olivier Lortholary; Sonja Koblinger; Heike Diekmann-Berndt; Oliver A Cornely
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

7.  Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Authors:  Thomas J Walsh; Hedy Teppler; Gerald R Donowitz; Johan A Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw
Journal:  N Engl J Med       Date:  2004-09-30       Impact factor: 91.245

8.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

Authors:  Jo-Anne H van Burik; Voravit Ratanatharathorn; Daniel E Stepan; Carole B Miller; Jeffrey H Lipton; David H Vesole; Nancy Bunin; Donna A Wall; John W Hiemenz; Yoichi Satoi; Jeanette M Lee; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-10-27       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.